Amit Hazan
Stock Analyst at Goldman Sachs
(2.14)
# 2,792
Out of 5,182 analysts
95
Total ratings
56.25%
Success rate
1.33%
Average return
Main Sectors:
Stocks Rated by Amit Hazan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSP Inspire Medical Systems | Upgrades: Buy | n/a | $54.42 | - | 3 | Dec 13, 2022 | |
| BVS Bioventus | Maintains: Neutral | $13 → $2.5 | $8.84 | -71.72% | 5 | Nov 30, 2022 | |
| SKIN The Beauty Health Company | Maintains: Buy | $22 → $19 | $0.88 | +2,066.48% | 4 | Nov 23, 2022 | |
| SHC Sotera Health Company | Maintains: Neutral | $9 → $8 | $14.64 | -45.36% | 4 | Nov 23, 2022 | |
| LIVN LivaNova | Maintains: Buy | $73 → $63 | $63.54 | -0.85% | 3 | Nov 23, 2022 | |
| BDX Becton, Dickinson and Company | Maintains: Buy | $319 → $272 | $154.96 | +75.53% | 8 | Nov 23, 2022 | |
| BLCO Bausch + Lomb | Maintains: Neutral | $19 → $17 | $15.92 | +6.78% | 3 | Nov 23, 2022 | |
| OM Outset Medical | Maintains: Buy | $510 → $435 | $4.10 | +10,509.76% | 2 | Nov 9, 2022 | |
| PRCT PROCEPT BioRobotics | Maintains: Neutral | $39 → $44 | $23.19 | +89.74% | 2 | Nov 4, 2022 | |
| EW Edwards Lifesciences | Maintains: Neutral | $97 → $73 | $80.84 | -9.70% | 3 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $60 → $53 | $16.62 | +218.89% | 11 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $57 | $22.52 | +153.11% | 1 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $11 → $9.5 | $11.03 | -13.87% | 2 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $111 → $104 | $101.83 | +2.13% | 7 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $80 → $60 | $21.82 | +174.98% | 3 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $129 → $115 | $86.42 | +33.07% | 9 | Jan 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $248 → $150 | $332.07 | -54.83% | 2 | Apr 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $46 | $61.86 | -25.64% | 1 | Feb 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $242 | $452.95 | -46.65% | 8 | Feb 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $177 | $91.40 | +93.65% | 5 | Feb 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $139 → $147 | $238.41 | -38.34% | 6 | Feb 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $3.5 → $3.9 | $0.38 | +937.51% | 3 | Nov 1, 2018 |
Inspire Medical Systems
Dec 13, 2022
Upgrades: Buy
Price Target: n/a
Current: $54.42
Upside: -
Bioventus
Nov 30, 2022
Maintains: Neutral
Price Target: $13 → $2.5
Current: $8.84
Upside: -71.72%
The Beauty Health Company
Nov 23, 2022
Maintains: Buy
Price Target: $22 → $19
Current: $0.88
Upside: +2,066.48%
Sotera Health Company
Nov 23, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $14.64
Upside: -45.36%
LivaNova
Nov 23, 2022
Maintains: Buy
Price Target: $73 → $63
Current: $63.54
Upside: -0.85%
Becton, Dickinson and Company
Nov 23, 2022
Maintains: Buy
Price Target: $319 → $272
Current: $154.96
Upside: +75.53%
Bausch + Lomb
Nov 23, 2022
Maintains: Neutral
Price Target: $19 → $17
Current: $15.92
Upside: +6.78%
Outset Medical
Nov 9, 2022
Maintains: Buy
Price Target: $510 → $435
Current: $4.10
Upside: +10,509.76%
PROCEPT BioRobotics
Nov 4, 2022
Maintains: Neutral
Price Target: $39 → $44
Current: $23.19
Upside: +89.74%
Edwards Lifesciences
Nov 3, 2022
Maintains: Neutral
Price Target: $97 → $73
Current: $80.84
Upside: -9.70%
Nov 3, 2022
Maintains: Sell
Price Target: $60 → $53
Current: $16.62
Upside: +218.89%
Oct 11, 2022
Initiates: Buy
Price Target: $57
Current: $22.52
Upside: +153.11%
Aug 8, 2022
Maintains: Neutral
Price Target: $11 → $9.5
Current: $11.03
Upside: -13.87%
Jul 25, 2022
Maintains: Sell
Price Target: $111 → $104
Current: $101.83
Upside: +2.13%
Jul 14, 2022
Maintains: Neutral
Price Target: $80 → $60
Current: $21.82
Upside: +174.98%
Jan 18, 2022
Maintains: Neutral
Price Target: $129 → $115
Current: $86.42
Upside: +33.07%
Apr 1, 2020
Downgrades: Sell
Price Target: $248 → $150
Current: $332.07
Upside: -54.83%
Feb 13, 2020
Initiates: Neutral
Price Target: $46
Current: $61.86
Upside: -25.64%
Feb 13, 2020
Initiates: Buy
Price Target: $242
Current: $452.95
Upside: -46.65%
Feb 13, 2020
Initiates: Buy
Price Target: $177
Current: $91.40
Upside: +93.65%
Feb 25, 2019
Maintains: Neutral
Price Target: $139 → $147
Current: $238.41
Upside: -38.34%
Nov 1, 2018
Upgrades: Neutral
Price Target: $3.5 → $3.9
Current: $0.38
Upside: +937.51%